We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+2.69%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$8.16B
AUM Growth
+$296M
Cap. Flow
-$1.61B
Cap. Flow %
-19.71%
Top 10 Hldgs %
74.41%
Holding
114
New
7
Increased
22
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$80.1M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$65.5M
3
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$58.8M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$48.9M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$35.8M

Top Sells

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$84.5M
2
CHTP
CHELSEA THERAPEUTICS INT'L LTD
CHTP
+$37.3M
3
HALO icon
Halozyme
HALO
+$24.8M
4
GILD icon
Gilead Sciences
GILD
+$23.4M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$18.6M

Sector Composition

Rank Sector Weight
1 Healthcare 44.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARWR icon
26
Arrowhead Research
ARWR
$12.3B
$20.5M 0.25%
1,430,802
+698,740
+95% +$9.16M
TGTX icon
27
TG Therapeutics
TGTX
$8.31B
$20.3M 0.25%
2,160,965
– –
XNPT
28
DELISTED
XENOPORT, INC.
XNPT
$19.5M 0.24%
4,034,112
– –
PGNX
29
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$19.2M 0.23%
4,449,797
– –
SLXP
30
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$16.5M 0.2%
133,721
+130,100
+3,593% +$14.4M
AEGR
31
DELISTED
Aegerion Pharmaceuticals
AEGR
$13.3M 0.16%
413,922
-100,000
-19% -$3.72M
OMER icon
32
Omeros
OMER
$1.39B
$13.1M 0.16%
753,804
– –
KYTH
33
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$11.9M 0.15%
311,255
– –
NGNE icon
34
Neurogene
NGNE
$773M
$11.4M 0.14%
60,593
– –
QLTI
35
DELISTED
QLT Inc
QLTI
$9.49M 0.12%
1,535,863
– –
AGIO icon
36
Agios Pharmaceuticals
AGIO
$1.98B
$9.16M 0.11%
199,893
– –
NBIX icon
37
Neurocrine Biosciences
NBIX
$15.5B
$8.23M 0.1%
554,590
+106,716
+24% +$1.51M
SGMO
38
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$7.98M 0.1%
522,764
– –
OSIR
39
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$7.98M 0.1%
510,606
+149,076
+41% +$2.19M
INFI
40
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$7.95M 0.1%
624,050
– –
BLUE
41
DELISTED
bluebird bio
BLUE
$7.65M 0.09%
15,306
– –
AERI
42
DELISTED
Aerie Pharmaceuticals
AERI
$7.42M 0.09%
299,356
– –
MTEM
43
DELISTED
Molecular Templates, Inc.
MTEM
$7.23M 0.09%
11,069
– –
SGYP
44
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$7.16M 0.09%
1,758,271
– –
IRWD icon
45
Ironwood Pharmaceuticals
IRWD
$709M
$6.84M 0.08%
532,715
– –
MGNX icon
46
MacroGenics
MGNX
$261M
$6.78M 0.08%
311,891
+215,726
+224% +$4.54M
EPZM
47
DELISTED
Epizyme, Inc
EPZM
$6.66M 0.08%
214,012
– –
ARRY
48
DELISTED
Array Biopharma Inc
ARRY
$6.54M 0.08%
1,433,797
– –
WINT
49
DELISTED
Windtree Therapeutics Inc
WINT
$6.5M 0.08%
260,866
– –
ABUS icon
50
Arbutus Biopharma
ABUS
$1.03B
$6.32M 0.08%
484,156
– –
1
2
3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2014 Portfolio in Review

As of Q2 2014, Julian Baker held 114 positions worth $8.16B, up 3.8% from $7.87B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Julian Baker withdrew a net $1.61B in Q2 2014, closing 9 positions and reducing 9 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $84.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 48% a quarter earlier.

Against the trend, Julian Baker opened a new position in Aravive, Inc. Common Stock worth $34.9M.

  • Julian Baker's largest Q2 2014 buy was Aravive, Inc. Common Stock: 207,648 shares worth $34.9M.
  • Julian Baker added most to PHARMACYCLICS INC in Q2 2014, an estimated $80.1M increase.
  • Julian Baker's biggest Q2 2014 reduction was Halozyme, cutting an estimated $24.8M.
  • Julian Baker fully exited Intercept Pharmaceuticals, Inc. in Q2 2014, selling an estimated $84.5M.
  • Julian Baker's ten largest holdings make up 74% of its $8.16B portfolio in Q2 2014.
  • Julian Baker opened 7 new positions and closed 9 in Q2 2014.
  • Julian Baker's portfolio value rose 3.8% quarter-over-quarter to $8.16B.

Based on Baker Bros. Advisors's 13F filing for Q2 2014, filed 14 Aug 2014.